FDMT — 4D Molecular Therapeutics Share News
0.000.00%
Last trade - 00:00- $710.99m
- $369.25m
- $85.21m
4D Molecular Therapeutics Q2 net loss widens
Brief: 4D Molecular Therapeutics Q2 Net Income USD -72.936 Million Vs. IBES Estimate USD -70.3 Million
4D Molecular Therapeutics Inc expected to post a loss of $1.02 a share - Earnings Preview
Brief: 4d Molecular Therapeutics Says 4D-150 Continues To Be Well Tolerated With No New Safety Findings
Brief: 4D Molecular Therapeutics Q1 Net Income USD -68.76 Million Vs. IBES Estimate USD -62.6 Million
U.S. RESEARCH ROUNDUP- Ferguson Enterprises, Hartford Insurance Group, JP Morgan
Brief: 4Dmt Completes Enrollment For 4Front-1 Phase 3 Clinical Trial Of 4D-150 In Wet AMD
Brief: 4Dmt Provides Company Update And Anticipated Development Milestones For 2026
U.S. RESEARCH ROUNDUP-Cencora, Eagle Materials, Honeywell
4D Molecular Therapeutics' Q3 revenue misses
Brief: 4D Molecular Therapeutics Q3 Net Income USD -56.876 Million Vs. IBES Estimate USD -56.2 Million
Brief: 4DMT Reports Long-Term Phase 1/2 Data Showing Durable Multi-Year Benefit of 4D-150 in Wet AMD
Brief: 4Dmt Announces Exclusive License Agreement With Otsuka Pharmaceutical For Development And Commercialization Of 4D-150 In Asia-Pacific
Brief: 4Dmt Advances 4D-710 To Phase 2 With Additional Funding
Brief: 4D Molecular Therapeutics Says On Sept 30, Appointed Ashoo Gupta As Principal Financial Officer - SEC Filing
4D Molecular Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
4D Molecular Therapeutics Q2 net loss widens to $54.7 mln
4D Molecular Therapeutics Inc expected to post a loss of 88 cents a share - Earnings Preview
Brief: 4D Molecular Therapeutics Says CFO Uneek Mehra To Resign